Study type: Human research · Status: Evidence verified by machine against declared source
Safety and Efficacy of Cerebrolysin in Infants with Communication Defects due to Severe Perinatal Brain Insult: A Randomized Controlled Clinical Trial
Journal of clinical neurology (Seoul, Korea) · 2016
Study scale: Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study scale
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Intervention or exposure
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Comparator
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Outcomes examined
The efficacy, tolerability, and safety of neuroreparative Cerebrolysin therapy has been confirmed in clinical trials involving adults with stroke and Alzheimer's disease.1112 Cerebrolysin is a porcine brain-derived preparation of low-molecular-weight neuropeptides (10 kDa) and free amino acids that exhibits pharmacodynamic properties similar to those of naturally occurring neurotrophic factors.13 Its mechanism of action is thought to be inhibition of apoptosis,14 and it has also been shown to improve synaptic plasticity and induce neurogenesis in a mouse model of Alzheimer's disease.1516 In adults, Cerebrolysin was shown to augment the proliferation, differentiation, and migration of adult subventricular zone (SVZ) neural progenitor cells (i.e., stem cells), contributing to neurogenesis; this finding may in part explain the improvement of neurological outcome with Cerebrolysin therapy after stroke.17
Key findings
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
Not reported in the declared source.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.